Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$5.02 - $6.59 $291,290 - $382,391
-58,026 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$6.5 - $10.53 $48,685 - $78,869
-7,490 Reduced 11.43%
58,026 $470,000
Q4 2020

Feb 16, 2021

SELL
$3.7 - $7.66 $316,634 - $655,519
-85,577 Reduced 56.64%
65,516 $423,000
Q3 2020

Nov 10, 2020

SELL
$3.45 - $4.89 $471,307 - $668,027
-136,611 Reduced 47.48%
151,093 $544,000
Q1 2020

May 15, 2020

BUY
$2.12 - $6.8 $609,932 - $1.96 Million
287,704 New
287,704 $982,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Thrivent Financial For Lutherans Portfolio

Follow Thrivent Financial For Lutherans and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.